Key milestones and insights from the evolution of antibody-drug conjugates – Zymeworks Inc.
Zymeworks Inc. shared a post on Linkedin:
”We’re proud to share a recent publication in Cancer Discovery (AACR Journals): ‘The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development’ by Raffaele Colombo, Jamie Rich, Paolo Tarantino, Patricia LoRusso, and Elisabeth (Liesbeth) de Vries.
This comprehensive review traces the evolution of antibody-drug conjugates (ADCs), highlighting key milestones and insights from four decades of research. Inspired by discussions at last year’s AACR-NCI-EORTC triple meeting, it offers valuable perspective on ADC development. We’re excited to contribute to the scientific community’s understanding of ADCs and their therapeutic potential.”
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Authors: Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, Patricia M. LoRusso, Elisabeth G.E. de Vries.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023